Chorlton
Alan Chorlton, Newmarket GB
Patent application number | Description | Published |
---|---|---|
20130158083 | METAXALONE COCRYSTALS - The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of metaxalone. Disclosed herein are several new cocrystals of metaxalone, including: a 1:1 metaxalone adipic acid cocrystal, a 1:0.5 metaxalone fumaric acid cocrystal, a 1:1 metaxalone salicyclic acid cocrystal, a 1:0.5 metaxalone succinic acid cocrystal, and a 1:0.5 metaxalone maleic acid cocrystal. The therapeutic uses of these metaxalone cocrystals are described as well as therapeutic compositions containing them. | 06-20-2013 |
20130203806 | CILOSTAZOL COCRYSTALS AND COMPOSITIONS - The invention relates to improvements of the physiochemical and/or the pharmaceutical properties of cilostazol. Disclosed herein are several new compositions and cocrystals of cilostazol, including: a 1:1 cilostazol gentisic acid cocrystal, a 1:1:1 cilostazol gentisic acid H | 08-08-2013 |
20130252949 | APREPITANT L-PROLINE COMPOSITION AND COCRYSTAL - A 1:1:1 aprepitant L-proline H | 09-26-2013 |
20140039005 | NOVEL REBAMIPIDE COMPLEXES AND COCRYSTALS - New rebamipide complexes and new rebamipide cocrystals are disclosed, specifically a 1:1 rebamipide nicotinamide complex, a 1:1 rebamipide nicotinamide cocrystal, a 1:1 rebamipide 2,4-dihydroxybenzolc acid complex, and a 1:1 rebamipide 2,4-dihydroxybenzoic acid cocrystal. Pharmaceutical compositions containing a rebamipide complex or cocrystal of the invention and a pharmaceutically acceptable carrier and methods of treatment are also disclosed. | 02-06-2014 |
Alan Chorlton, Newmarket Suffolk GB
Patent application number | Description | Published |
---|---|---|
20140343060 | APREPITANT L-PROLINE SOLVATES - COMPOSITIONS AND COCRYSTALS - Aprepitant L-proline solvate compositions and aprepitant L-proline solvate cocrystals are disclosed as well as pharmaceutical compositions containing them. The compositions and cocrystals of the invention are: 1:1:1 aprepitant L-proline methanol composition; a 1:1:1 aprepitant L-proline methanol cocrystal; a 1:1:1:1 aprepitant L-proline ethanol composition; a 1:1:1 aprepitant L-proline ethanol cocrystal; l 1:1:1 aprepitant L-proline n-propanol composition; and a 1:1:1 aprepitant L-proline n-propanol cocrystal: The aprepitant L-proline solvate compositions or cocrystals may be used in the same way as aprepitant to treat or prevent disorders relating to emesis, a neuropsychiatric disease, an inflammatory disease, pain, cancer, a skin disease, itch a respiratory disease, or an addiction. | 11-20-2014 |
Alan Patrick Chorlton, Cambridgeshire GB
Patent application number | Description | Published |
---|---|---|
20110245306 | CO-CRYSTALS - The present invention relates to co-crystals of propiconazole and a co-crystal forming compound. | 10-06-2011 |
James Chorlton, Gerrards Cross GB
Patent application number | Description | Published |
---|---|---|
20080267996 | Compositions for inducing an immune response against hepatitis B - The present invention is directed to a method of inducing an immune response against a hepatitis B antigen (e.g., an antigen from a hepatitis B virus) in a mammal, which comprises administering to the mammal a priming composition (e.g., a DNA plasmid), comprising a source of one or more epitopes of the hepatitis B target antigen; and a boosting composition, comprising a source of one or more eptiopes of the hepatitis B target antigen (e.g., a non-replication or replication-impaired poxvirus such as MVA), wherein at least one epitope of the boosting composition is identical to an epitope of the priming composition. The present invention also is directed to a method of inducing an immune response against a hepatitis B antigen (e.g., an antigen from a hepatitis B virus) in a mammal, which comprises administering to the mammal a priming composition (e.g., a DNA plasmid), comprising a source of one or more epitopes of the hepatitis B target antigen. In addition, the present invention is directed to compositions for use in the methods of the present invention. | 10-30-2008 |